PFE - Zentalis Pharmaceuticals Seeks Development Funding From IPO
Quick Take
Zentalis Pharmaceuticals (ZNTL) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement.
The firm is developing a pipeline of small molecule therapeutics targeting patients with breast cancer, solid tumors, blood cancers or lung cancer.
ZNTL has a promising collaboration with Pfizer for its lead candidate in combination with Pfizer’s ER+/HER- treatment and also as a monotherapy.
I’ll provide a final opinion when we get further pricing and valuation details from management.
Company & Technology
New York, New York-based Zentalis was